Clinical trials: sponsored by UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer, Metastatic Cancer
Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET imaging, may be effective in detecting residual disease after radiofrequency ablation of liver metastases in patients with colorectal cancer.
- Trial name
- NCT00499395
- Testing
- positron emission tomography, radiofrequency ablation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery
RATIONALE: Comparing results of diagnostic procedures, such as molecular marker profiling, done before and after chemotherapy, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00233974
- Testing
- PET (positron emission tomography)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- NCT00266097
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with…
- Trial name
- NCT00227032
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00998101
- Testing
- cetuximab, carboplatin, ixabepilone
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00520000
- Testing
- Carboplatin, Abraxane
- Volunteers
- 47 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Depression, Fatigue
Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia
RATIONALE: An individualized exercise program may be effective in lessening fatigue and depression and improving quality of life in patients undergoing chemotherapy for leukemia.
- Conditions
- Depression, Fatigue, Leukemia, Musculoskeletal Complications
- Trial name
- NCT00499759
- Testing
- Resting vitals, Body Composition, Timed Get-up and Go test (TGUG).
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003392
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Liver Cancer
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
RATIONALE: Octreotide may stop or slow the growth of tumor cells and may be an effective treatment for liver cancer. PURPOSE: This phase II trial is studying how well octreotide works in treating patients with locally advanced or…
- Trial name
- NCT00257426
- Testing
- octreotide acetate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00006108
- Testing
- trastuzumab, capecitabine, paclitaxel
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100 mg/m2 e3w).
- Trial name
- NCT00123929
- Testing
- docetaxel, doxorubicin
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital San Carlos, Madrid
Methionine Adenosyltransferase Deficiency, Metabolism, Inborn Errors
Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency
OBJECTIVES: I. Determine whether plasma choline and breast milk choline levels are low at fasting in a patient with methionine adenosyltransferase deficiency, and if the choline levels are low, determine whether choline levels…
- Trial name
- NCT00006061
- Testing
- phosphatidylcholine
- Volunteers
- 1 people
- Sponsor
- National Center for Research Resources (NCRR)